OncRef

Clinical Trial: NCT04656652

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 3

Lead Sponsor:Daiichi Sankyo
Information Provided By:Daiichi Sankyo
Last Update Posted:2026-08-26

Study Overview

Brief Summary

This study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations.

Official Title

Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-LUNG01)

Conditions

Non-small Cell Lung Cancer

Intervention / Treatment

  • Drug: DS-1062a
  • Drug: Docetaxel

Other Study ID Numbers

  • DS1062-A-U301
  • 2020-004643-80
  • 2023-509865-19-00
  • 2023

Start Date (Actual)

2020-12-21

Primary Completion Date (Actual)

2024-05-10

Study Completion Date (Estimated)

2027-02-15

Enrollment (Actual)

605

Study Type

Interventional

Phase

Phase 3